Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 10/20 | 0.66 |
| ▸ | CHUK | O15111 | 9/20 | 0.66 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.53 |
| ▸ | CCNC | P24863 | 2/20 | 0.52 |
| ▸ | CDK8 | P49336 | 2/20 | 0.52 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14021219 | 0.90 | PIK3CA (0.58) | IKBKBCHUKPIK3CAPIK3CBPIK3CG | |
| SCHEMBL14021011 | 0.90 | MKNK2 (0.65) | IKBKBCHUKMKNK1PIK3CAPIK3CB | |
| SCHEMBL14021190 | 0.89 | MTOR (0.60) | IKBKBCHUKPIK3CAPIK3CBPIK3CG | |
| SCHEMBL11924733 | 0.89 | MTOR (0.60) | IKBKBCHUKPIK3CAPIK3CBPIK3CG | |
| SCHEMBL14063828 | 0.88 | CAMK2D (0.61) | IKBKBCHUKPIK3CAPIK3CBPIK3CG | |
| SCHEMBL7020880 | 0.88 | PIK3CA (0.56) | IKBKBCHUKPIK3CAPIK3CBPIK3CG | |
| SCHEMBL14021274 | 0.88 | IKBKB (0.55) | IKBKBCHUKPIK3CAPIK3CBPIK3CG | |
| SCHEMBL14021276 | 0.88 | IKBKB (0.55) | IKBKBCHUKPIK3CAPIK3CBPIK3CG | |
| SCHEMBL14021271 | 0.88 | IKBKB (0.55) | IKBKBCHUKPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4065429 | 0.88 | IKBKB (0.54) | IKBKBCHUKPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327788-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION (US) | 2017-11-16 | — | — | US | disclosed |
| US-9725694-B2 | Composition for collecting and preserving placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| US-9598669-B2 | Composition for collecting placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1931322-B1 | IKK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MERCK SERONO SA (CH) | 2012-08-15 | — | — | EP | disclosed |
| EP-2266561-A2 | IKK Inhibitors for the Treatment of Endometriosis | Merck Serono S.A. (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20100069387-A1 | IKK Inhibitors for the Treatment of Endometriosis | MERCK SERONO SA (CH) | 2010-03-18 | — | — | US | disclosed |
| EP-1349841-B1 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1349841-B1 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2004084901-A1 | METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040106634-A1 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-06-03 | — | — | US | disclosed |
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | disclosed |
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | disclosed |
| US-20030220330-A1 | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2003-11-27 | — | — | US | disclosed |
| US-20030203926-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2003-10-30 | — | — | US | disclosed |
| EP-1349841-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-1349840-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002046170-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046171-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106634-A1 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | MAPK6, MAPKAPK2, DUSP6 | IKBKB 91/4885CHUK 69/4885MKNK1 144/4885 |
| US-20030203926-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | NFKBIA, IKBKB, IKBKE | IKBKB 2/4885CHUK 4/4885MKNK1 241/4885 |
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | MAP3K1, MAP3K6, MAPKAPK2 | IKBKB 110/4885CHUK 58/4885MKNK1 97/4885 |
| US-20100069387-A1 | IKK Inhibitors for the Treatment of Endometriosis | NFKBIA, IKBKG, IKBKE | IKBKB 4/4885CHUK 5/4885MKNK1 62/4885 |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | IKBKB 755/4885CHUK 433/4885MKNK1 173/4885 |
| US-20030220330-A1 | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto | MAPK6, MAP3K6, MAPK1 | IKBKB 95/4885CHUK 38/4885MKNK1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.